HealthEquity (HQY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Werte in diesem Artikel
For the quarter ended January 2025, HealthEquity (HQY) reported revenue of $311.82 million, up 18.8% over the same period last year. EPS came in at $0.69, compared to $0.63 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $305.1 million, representing a surprise of +2.20%. The company delivered an EPS surprise of -2.82%, with the consensus EPS estimate being $0.71.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how HealthEquity performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total HSA Assets: $32.11 billion compared to the $31.65 billion average estimate based on three analysts. Total HSA investments: $14.68 billion compared to the $14.18 billion average estimate based on three analysts. CDBs Accounts: 7.14 million versus 6.87 million estimated by three analysts on average. Total Accounts: 17.03 million versus the three-analyst average estimate of 16.53 million. Total HSA cash: $17.44 billion versus the three-analyst average estimate of $17.48 billion. HSAs Accounts: 9.89 million versus 9.67 million estimated by three analysts on average. Revenue- Service: $124.21 million versus the four-analyst average estimate of $122.45 million. The reported number represents a year-over-year change of +4.8%. Revenue- Custodial: $144.13 million versus $140.18 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +36.7% change. Revenue- Interchange: $43.48 million versus $41.27 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.3% change. View all Key Company Metrics for HealthEquity here>>>Shares of HealthEquity have returned -10.6% over the past month versus the Zacks S&P 500 composite's -7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report HealthEquity, Inc. (HQY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: HealthEquity und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf HealthEquity
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf HealthEquity
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu HealthEquity Inc
Analysen zu HealthEquity Inc
Datum | Rating | Analyst | |
---|---|---|---|
07.02.2019 | HealthEquity Buy | Chardan Capital Markets | |
20.03.2018 | HealthEquity Buy | Chardan Capital Markets | |
06.12.2017 | HealthEquity Buy | Chardan Capital Markets | |
07.06.2017 | HealthEquity Buy | Chardan Capital Markets | |
31.03.2017 | HealthEquity Overweight | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
07.02.2019 | HealthEquity Buy | Chardan Capital Markets | |
20.03.2018 | HealthEquity Buy | Chardan Capital Markets | |
06.12.2017 | HealthEquity Buy | Chardan Capital Markets | |
07.06.2017 | HealthEquity Buy | Chardan Capital Markets | |
31.03.2017 | HealthEquity Overweight | Cantor Fitzgerald |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für HealthEquity Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen